Kainate/estrogen receptor involvement in rapid estradiol effects in vitro and intracellular signaling pathways.
Although the interactions between sex steroids and GnRH have been extensively studied, little is known about the mechanism of estradiol (E2) effects on GnRH secretion. In the present study, we used retrochiasmatic hypothalamic explants of 50-d-old male rats, and we observed that E2 significantly increased the glutamate-evoked GnRH secretion in vitro within 15 min in a dose-dependent manner. E2 also significantly increased the L-arginine-evoked GnRH secretion. E2 effects were time dependent because the initially ineffective 10(-9) M concentration became effective after 5 h of incubation. The E2 effects involved the estrogen receptor (ER) alpha because they were similarly obtained with the specific ER alpha agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole. The use of glutamate receptor agonists and antagonists indicated that E2 effects on GnRH secretion evoked by both glutamate and L-arginine involved the 2-amino-3-hydroxy-5-methyl-4-isoxazol propionic acid/kainate receptors. Similar E2 effects on the kainate-evoked secretion were observed throughout development in both sexes. The observation of similar E2 effects using explants containing the median eminence alone indicated that the median eminence was a direct target for E2 rapid effects on the glutamate-evoked GnRH secretion. The signaling pathways involved in E2 effects included an increase in intracellular calcium and the activation of protein kinase A, protein kinase C, and MAPK. It is concluded that E2 can stimulate the glutamate- and nitric oxide-evoked GnRH secretion in vitro through a rapid pathway involving the ER and kainate receptor as well as through a slower mechanism responding to lower E2 concentrations.
Matagne
V
V
Developmental Neuroendocrinology Unit, Research Center for Cellular and Molecular Neurobiology, University of Liège, Centre Hospitalier Universitaire, Sart-Tilman, B-4000 Liège, Belgium.
Lebrethon
M-C
MC
Gérard
A
A
Bourguignon
J-P
JP
D000375:Aging; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology*; D047628:Estrogen Receptor alpha / Q000819:agonists / Q000502:physiology; D005260:Female; D018698:Glutamic Acid / Q000494:pharmacology; D007987:Gonadotropin-Releasing Hormone / Q000378:metabolism*; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008473:Median Eminence / Q000187:drug effects / Q000378:metabolism; D009569:Nitric Oxide / Q000494:pharmacology; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000502:physiology*; D017470:Receptors, Glutamate / Q000187:drug effects / Q000502:physiology; D018092:Kainic Acid Receptors / Q000187:drug effects / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
D001120:Arginine; D004958:Estradiol; D047628:Estrogen Receptor alpha; D018698:Glutamic Acid; D007987:Gonadotropin-Releasing Hormone; D009569:Nitric Oxide; D011960:Receptors, Estrogen; D017470:Receptors, Glutamate; D018092:Kainic Acid Receptors